COVID-19 ACIP Vaccine Recommendations
Advisory Committee on Immunization Practices (ACIP)
CDC now recommends that children between the ages of 5 and 11 years receive the Pfizer-BioNTech pediatric COVID-19 Vaccine. Get more information and read CDC’s media statement.
Published in Morbidity and Mortality Weekly Report (MMWR)
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).
CURRENT COVID-19 Vaccine Recommendations
- MMWR; August 13, 2021;70
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
Print version pdf icon[6 pages] - MMWR; July 9, 2021;70
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
Print version pdf icon[6 pages] - MMWR; May 14, 2021;70
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
Print version pdf icon[4 pages]- See also:
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine for Persons Aged 12-15 Years
- ACIP Evidence to Recommendations for Use of Pfizer-BioNTech COVID-19 Vaccine under an Emergency Use Authorization
- Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine
- See also:
- MMWR; April 30, 2021;70
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021- See also:
- MMWR; March 2, 2021;70
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
Print version pdf icon[4 pages]- See also:
- ACIP Evidence to Recommendations for Use of Janssen COVID-19 Vaccine under an Emergency Use Authorization
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Janssen COVID-19 Vaccine
- Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Janssen COVID-19 Vaccine
- See also:
- MMWR; December 22, 2020;69
The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020
Print version pdf icon[5 pages]
- MMWR; December 20, 2020;69
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
Print version pdf icon[4 pages]
- MMWR; December 13, 2020;69
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020
Print version pdf icon[3 pages] - MMWR; December 3, 2020;69
The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020
Print version pdf icon[3 pages]- See also:
Page last reviewed: August 30, 2021
Content source: National Center for Immunization and Respiratory Diseases